We undertook studies focused on folate acquisition by Chlamydia trachomatis L2, Chlamydia psittaci 6BC, and C. psittaci francis. Results from in situ studies, using wild-type host cells, confirmed that C. trachomatis L2 and C. psittaci 6BC are sensitive to sulfonamides whereas C. psittaci francis is resistant. In addition C. trachomatis L2 and C. psittaci francis were inhibited by methotrexate in situ whereas C. psittaci 6BC was not. In contrast to C. trachomatis, neither C. psittaci strain was affected by trimethoprim. Surprisingly our results indicate that all three strains are capable of efficient growth in folate-depleted host cells. When growing in folate-depleted cells C. psittaci francis becomes sensitive to sulfonamide. The ability of all three strains to carry out de novo folate synthesis was demonstrated by following the incorporation of exogenous 13HJpABA into intracellular folates and by detecting dihydropteroate synthase activity in reticulate body crude extract. Dihydrofolate reductase activity was also detected in reticulate body extract. In aggregate the results indicate that C. trachomatis L2, C.
1. Abbreviations used in this paper: CHO, Chinese hamster ovary; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; EB, elementary body; H2folate, dihydrofolate; H4folate, tetrahydrofolate; ID_0, antimetabolite concentration required to reduce incorporation of radiolabel into DNA by 50%; pABA, para-aminobenzoic acid; RB, reticulate body.
encountered. Once inside a host cell EBs differentiate to RBs, which divide by binary fission within the confines of a membrane bound cytoplasmic vacuole. Chlamydiae have an absolute nutritional dependency on the host cell to provide a wide variety of intermediates of metabolism. After multiple rounds of division RBs differentiate back to EBs, which are subsequently released from the host cell to begin a new infection cycle.
The genus chlamydiae is currently divided into three species, Chlamydia trachomatis, Chlamydia psittaci, and Chiamydia pneumoniae (5) (6) (7) . Classically, the species have been differentiated by inclusion morphology (diffuse vs. compact), presence or absence ofglycogen within the inclusion (as determined by iodine staining), and differing sensitivity to sulfa drugs. C. trachomatis is sensitive to sulfonamides and they develop diffuse glycogen containing inclusions. In contrast C. psittaci, with the exception of strain 6BC, is resistant to sulfa drugs and they give rise to dense inclusions that lack glycogen. C. pneumoniae is also resistant to sulfonamides and they yield dense inclusions that do not contain glycogen. Sulfonamides are structural analogues and competitive antagonists of para-aminobenzoic acid (pABA), and thus prevent normal bacterial use of pABA for the de novo synthesis of folic acid (8) . More specifically, sulfonamides are competitive inhibitors of the bacterial enzyme dihydropteroate synthase (DHPS), which catalyzes the incorporation of pABA into dihydropteroic acid, the immediate precursor of folic acid. As such, microorganisms that are sensitive to sulfonamides must synthesize their own folates and those that can use preformed folates are resistant to sulfa drugs. Mammalian cells are not affected by sulfonamides because they must obtain preformed folates from dietary sources.
The biologically active form of folate is tetrahydrofolate (H4folate), which functions as a one-carbon unit carrier in a variety ofbiosynthetic reactions, including methionine biosynthesis, thymidylate synthesis, and purine biosynthesis (9, 10) . Thymidylate synthesis is unique among the biosynthetic reactions that employ H4folate as cofactor in that it involves not only the transfer ofa one-carbon moiety but also the oxidation ofthe carrier ( 11 ) . The dihydrofolate (H2folate) formed is converted back to H4folate by the enzyme dihydrofolate reductase (DHFR). H4Folate is again converted to a cofactor by the addition of a one-carbon unit as catalyzed by serine hydroxymethyltransferase. Together these reactions form the thymidylate cycle as represented schematically in Fig. 1 .
Both C. psittaci and C. trachomatis have been shown to contain folates different from those present in their host cells ( 12, 13) . In addition several studies have shown that chlamydiae cannot use medium-supplied thymidine (14) (15) (16) (17) , however, they can incorporate exogenously supplied uridine into parasite DNA ( 1 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ( 17) . EB infectivity was titered as previously described ( 17) . Confluent monolayers (3-4 x 106 cells per 5-cm plate) of wild-type CHO Kl and DHFR-deficient CHO cells were infected at a multiplicity of infection of three to five inclusion-forming units per cell, which resulted in 90-100% infection with little host cell toxicity. C. trachomatis L2 and C. psittaci 6BC and francis were grown in the presence ofcycloheximide, 1 ug/ml ofculture medium, as previously described ( 16, 17) . Mock-infected host cell cultures were treated in the same fashion as infected cultures except that chlamydiae were not added.
Suspension cultures of mouse L cells were used as host for preparing large batches of RBs, which were highly purified through Renografin density gradients as described previously ( 17) . Purified RBs were lysed and extract for enzyme assays was prepared as described by Fan et al. ( 17) .
Measurement ofchlamydial DNA synthesis activity in situ. Chlamydial DNA synthesis activity was measured in situ by monitoring the incorporation of [6-3H] uridine into DNA in the presence ofcycloheximide as previously described ( 16, 17) . This DNA synthesis assay specifically measures chlamydial DNA synthesis activity and provides an accurate and reliable estimation of chlamydial growth ( 16 ately after infection with chlamydiae the cell monolayer was rinsed with Hanks' buffered saline, then 15 ml ofDME H-2 1 medium supplemented with 10% dialyzed fetal bovine serum, 0.3 mM proline, 0.3 mM glycine, 30MuM hypoxanthine, I Ag/ml cycloheximide, and 30 sCi
[3H]pABA was added to each flask. The cultures, both mock-and chlamydiae-infected, were incubated at 370C for 24 h and then the cells were harvested and intracellular folates were extracted as previously described (23) . Briefly, the monolayers were washed five times with ice-cold PBS then the cells were harvested in 1 ml of PBS by scraping the surface of the flask with a rubber policeman. The cells were heated at 1000C for 1 min in 3% sodium ascorbate, pH 6.0, and 3% 2-mercaptoethanol and then the cell debris were removed by centrifugation. The cell supernatant was treated with 0.5 ml ofpartially purified hog kidney polyglutamate hydrolase, prepared according to the method of McMartin et al. (24) , at 370C for 30 min to convert all folates to monoglutamates. After an additional boiling with ascorbate and 2-mercaptoethanol, the folates were extracted into methanol using a C-1 8 cartridge (Sep-Pak; Waters Chromatography Division, Milford, MA) and concentrated under a steady stream of nitrogen. The dried sample was dissolved in 100 l of 5 mM PIC A (Waters Chromatography Division) and the individual folates were resolved by HPLC using a C-8 ,uBondapak column (12.5 cm; Whatman International, Clifton, NJ) under isocratic conditions; the mobile phase consisted of 22.5% methanol and 77.5% 5 mM PIC A, pH 5.5. Isotope incorporation into individual folates was determined by in-line radioactive flow detection ( 171 detector; Beckman Instruments, Fullerton, CA). The identity of the radioactive peaks was confirmed by simultaneously monitoring the A290 ( 1066 UV detector; Beckman Instruments) of known unlabeled folate standards that were coinjected with each sample. Data were collected and processed with an IBM PC 50 using Beckman System Gold software.
Assay ofDHPS activity in vitro. DHPS was assayed by previously described procedures (25) with the following modifications. The DHPS assay mix contained, in a final volume of 100 Al, 100 mM Tris-HCl (pH 8.5), 5 mM NaF, 10 mM MgCl2, 10 AM H2PtCH2OPP, 1 MM [3H]pABA (10 MCi/ml), and 5 mM dithiothreitol. The reaction was initiated by the addition of 150 ig RB extract protein as a source of enzyme and then was allowed to proceed at 37°C for 60 min. The reaction was terminated by the addition of 100 A of 3% ascorbate/3% 2-mercaptoethanol followed by boiling for 1 min. The resulting precipitate was removed by centrifugation ( 14,000 g for 10 min) and then 50 jAl ofthe supernatant was spotted onto 3 X 30-cm strips of 3MM chromatography paper (Whatman International). The strips were developed in a descending chromatography tank using a mobile phase buffer of 0.1 M KH2PO4, pH 7.0. Once the buffer front had traveled 20 cm, the paper strip was removed from the chromatography tank, the origin containing the labeled product was cut from the strip, dried, and placed in a scintillation vial containing 10 ml cocktail (Universol; ICN Biomedicals, Inc., Costa Mesa, CA). The vial was left at room temperature for 16 h and then it was counted in a liquid scintillation counter (LS 5000; Beckman Instruments).
Assay of DHFR activity in vitro. DHFR assays were carried out essentially as described by Baccanari et al. (26) . The (28, 29) it is difficult to determine whether methotrexate inhibits chlamydiae directly or indirectly via an effect on the host cell line. This is particularly relevant when one considers that methotrexate inhibits de novo purine biosynthesis in mammalian cells (28, 29) and chlamydiae are auxotrophic for purine ribonucleotides (4, 5) . To determine whether methotrexate directly affects chlamydiae replication, we used a DHFR-deficient CHO cell line as a host to support parasite growth. As a result of the DHFR deficiency this cell line is unable to regenerate H4folate from H2folate and is unaffected by methotrexate ( 17, 22) . Methotrexate was an effective inhibitor of chlamydial growth in this cell line (Fig. 3) plemented with hypoxanthine, proline, glycine, and thymidine. Results presented in Table I indicate that all three chlamydial strains grew as well in CHO Kl cells extensively starved for folates and pABA as they did in host cells that had been previously cultured in complete medium. The observation that C. trachomatis L2 and C. psittaci 6BC could grow in folate-depleted host cells is in keeping with their sulfa sensitivity and further supports the suggestion that these two strains can synthesize folates de novo. However, given that C. psittaci francis was resistant to sulfonamide (a result that suggested that it could obtain preformed folates from the host) we were surprised that it could grow so well in host cells depleted of folates. To help clarify this paradox we checked the sulfonamide sensitivity of C. psittaci francis growing in host cells depleted of folates. The results clearly showed that, in contrast to the findings with folate-replete cells, C. psittaci francis was highly susceptible to sulfisoxazole inhibition when grown in folatestarved cells (Fig. 4) Detection ofin vitro DHPS activity in chlamydial extracts. To conclusively show that chlamydiae contain DHPS, we prepared extracts from highly purified C. trachomatis L2 and C. psittaci strains 6BC and francis RBs and then assayed for DHPS activity in vitro. DHPS activity was measured by following the synthesis ofdihydropteroate from [ 3H I pABA and 6-hydroxymethyl-7,8-dihydropterin pyrophosphate. We consistently detected DHPS activity using RB extract prepared from any one of the three chlamydial strains as a source of enzyme. RB extracts prepared from C trachomatis L2, C. psittaci 6BC, Reversal ofsuifisoxazole inhibition by pABA andfolates. It has been shown with numerous experimental systems that the inhibitory action of sulfa drugs can be antagonized by pABA (8) . Results presented in Fig. 6 indicate that, with folate-and pABA-depleted CHO Ki cells as host, the growth inhibition caused by 1 MM sulfisoxazole (Fig. 6 A-C, hatched bars) on all three strains of chlamydiae can be completely reversed by 0.1 ,uM pABA (Fig. 6 A-C, cross-hatched bars) . With C. psittaci francis, 10 MM folic acid completely reversed the inhibition caused by 1 MM sulfisoxazole (Fig. 6 C, square-checked bar) . Even 1 MM folic acid was sufficient to reverse 1 MM sulfisoxazole-induced inhibition (data not shown). In contrast, folic acid was much less effective at reversing the effects of sulfa on C. trachomatis L2 and C. psittaci 6BC, showing essentially no antagonism at 10 MM (Fig. 6 A and B , square-checked bars) and only partial reversion at 100 MM (data not shown). We found that the inhibitory effects of 1 MM sulfisoxazole on C. trachomatis L2 and C. psittaci francis could be partially and completely reversed, respectively, by 1 MuM 5-CHO-H4folate ( 5-CHO-H4folate completely reversed the inhibitory effects of 1 ,qM sulfisoxazole on C. trachomatis L2 (Fig. 6 A, open bar) . Surprisingly, even though methotrexate did not inhibit the growth of C. psittaci strain 6BC (Fig. 2) , we found that 10 jM 5-CHO-H4folate could reverse the effects of 1 gM sulfisoxazole (Fig. 6 B, open bar) .
Our commercial preparation of folic acid was 98% pure, therefore it was possible that a small amount ofcontaminating pABA may have been present in our folate preparations. Since pABA was 2 100 times more effective at antagonizing sulfa activity compared with 5-CHO-H4folate it was possible that the reversion brought about by folates was really caused by contaminating pABA.
To eliminate this possibility we tested the ability of folinic acid to reverse the inhibitory action oftrimethoprim/ sulfisoxazole against C. trachomatis L2. The results clearly show that 5-CHO-H4folate can antagonize the combined activity ofthe DHFR inhibitor trimethoprim and the DHPS inhibitor sulfisoxazole (Table II) . As expected folic acid could not reverse trimethoprim inhibition of C. trachomatis L2 growth (data not shown). Detection ofin vitro DHFR activity in chlamydial extracts. To directly demonstrate that chlamydiae encode DHFR we conducted in vitro assays for DHFR using extract prepared from highly purified RBs as a source of enzyme (Table III) . As a control experiment we conducted DHFR assays with crude extract prepared from logarithmically growing wild-type mouse L cells. We consistently detected DHFR activity in extracts prepared from C. trachomatis L2 as well as C. psittaci 6BC and francis RBs. The formation of tetrahydrofolate was dependent on the presence of RB extract, NADPH2, and H2fo-late (data not shown). No activity was detected iffolic acid was used as substrate. Mock infected mouse cell extract had essentially no DHFR activity.
Similar to in situ results we found that trimethoprim was a highly effective inhibitor of C. trachomatis L2 DHFR activity in vitro, however, it was less effective against C. psittaci 6BC (32) , we found that it was active against in vitro DHFR activity of all three chlamydial strains.
Discussion
Although there was no conclusive evidence until recently ( 17) , it has been assumed that chlamydiae require folates for the generation of thymidine nucleotides (5, 15) . Furthermore, it has generally been accepted that all C. trachomatis strains are sensitive to sulfonamides whereas all C. psittaci strains, with the exception of 6BC, are resistant to sulfa action ( 1, 4, 5, 12, (18) (19) (20) . A reasonable explanation for these findings was that C. trachomatis strains and C. psittaci 6BC were capable of synthesizing folates de novo whereas the remainder of the C. psittaci strains were not. Unlike the simple interpretation required to explain the action of sulfonamides against chlamydiae it has proven difficult to interpret results obtained using antifols that target DHFR (5, 19, 33 (34) .
In agreement with earlier in situ observations ( 12, 18) , we found that C. trachomatis L2 and C. psittaci 6BC were sensitive to sulfonamides. Furthermore, C. psittaci francis was resistant to sulfonamide, so long as folates were present in the culture medium. In addition our results indicate that trimethoprim was active against C. trachomatis L2 in situ but had no effect against either C. psittaci strain. Methotrexate inhibited the growth of C. trachomatis L2 and C. psittaci francis but did not effect C. psittaci 6BC growth. Previously Morgan ( 19) (30) and that C. psittaci francis is more efficient at ob-taining both reduced and nonreduced forms offolates from the host cell than are C. trachomatis L2 or C. psittaci 6BC. This hypothesis is also supported by the observation that when folates are present in the culture medium C. psittaci francis does not depend on de novo folate synthesis (as indicated by sulfa resistance) whereas C. trachomatis L2 and C. psittaci 6BC do (as indicated by sulfa sensitivity).
We consistently found that there was a difference in the composition ofthe intracellular folate pools between C. trachomatis and C. psittaci species. Although reduced folates were predominant in both chlamydial species, the C. trachomatis L2 folate pool was dominated by H4folate whereas the C. psittaci 6BC folate pool was dominated by reduced folates carrying a one-carbon unit (i.e., 10-CHO-H4folate). At the present time the significance of this difference is not known. However, it is interesting that, using the classical microbiological assay with Lactobacillus casei and Pediococcus cerevisiae, Colon and Moulder ( 31 ) also detected a difference in the composition of chlamydial species folate pools.
Our ability to detect DHFR activity in RB extracts from all three chlamydial strains confirm that the parasite does encode a DHFR. Results of in vitro DHFR assays indicate that the enzyme from all three strains is sensitive to methotrexate. In agreement with in situ results, we found that trimethoprim was a good inhibitor of C. trachomatis L2 DHFR activity in vitro. Both strains of C. psittaci were resistant to trimethoprim in situ and the in vitro DHFR activities of these two strains were less' sensitive to trimethoprim than was C. trachomatis L2 DHFR activity in vitro. However, the difference in in vitro sensitivity between the species was not as great as might have been expected given the large difference in trimethoprim sensitivity in situ. This raises the possibility that there could be differences in the way C. trachomatis and C. psittaci metabolize trimethoprim or in their intrinsic permeability to the drug.
It is evident from the results presented that no simple concluding statement can be made with regard to folate metabolism in chlamydiae. The vast majority of free-living bacteria, both pathogenic and nonpathogenic, lack transport system(s) for preformed folates and thus depend on de novo synthesis. Recent studies on a variety of parasitic protozoa have shown that both de novo synthesis and salvage pathways for folates exist in eucaryotic intracellular parasites (36) (37) (38) (39) (40) . Intracellular parasites spend most of their lives within host cells rich in nutrients. To obtain nondiffusible nutrients from their host, intracellular parasites must evolve (or obtain) suitable transport systems. Once a parasite has acquired the ability to obtain complex nutrients from its host it can afford to loose the capability to synthesize the given nutrient de novo. There would likely be a period of time when both capacities overlap and in some instances it may be necessary for the parasite to retain both pathways.
We believe that folate metabolism in chlamydiae is currently at this stage in evolution. All strains have an absolute dependence on folates for de novo thymidine synthesis. Originally this need was likely fulfilled via de novo folate synthesis as suggested by the ability ofall strains tested to incorporate exogenous pABA into folates. More recently chlamydiae has obtained the necessary genetic information to allow them to acquire preformed folates from their host. The current status of the folate transport system(s) appears to vary from strain to strain. At one extreme C. psittaci francis fulfills its needs for folate strictly by transporting preformed host folates but does retain the capacity to synthesize de novo. At the other extreme C. psittaci 6BC appears to depend almost exclusively on its ability to synthesize folates de novo, however, it also has the capacity to transport reduced folate to a limited extent. Much of the discrepancy in the literature regarding the effectiveness ofantifols against chlamydiae, both in situ and clinically, probably results from the parasites variable dependence on the two folate acquisition pathways.
